2,575 Shares in Moderna, Inc. $MRNA Bought by Brighton Jones LLC

Brighton Jones LLC bought a new position in Moderna, Inc. (NASDAQ:MRNA) during the third quarter, according to its most recent filing with the SEC. The firm bought 2,575 shares of the company’s stock, valued at approximately $496,000.

Other hedge funds have also bought and sold shares of the company. BlackRock Inc. bought a new position in Moderna in the 2nd quarter valued at about $2,142,877,000. Theleme Partners LLP purchased a new stake in Moderna in the 2nd quarter valued at $564,272,000. Wellington Management Group LLP raised its position in Moderna by 4.4% in the 2nd quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock valued at $172,384,000 after buying an additional 103,977 shares during the last quarter. Merck & Co. Inc. bought a new position in Moderna during the 2nd quarter valued at $161,642,545. Finally, Bamco Inc. NY bought a new position in Moderna during the 2nd quarter valued at $139,317,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

More Moderna News

Investors following MRNA have been watching these news items:

• Positive Sentiment: Moderna lifted its 2026 revenue-growth forecast to 15%–25%, from a previous outlook of up to 10%, citing commercial progress including stronger overseas COVID-19 sales. Article
• Positive Sentiment: The company highlighted progress in its oncology pipeline, including its personalized cancer vaccine, positioning cancer treatments as a potential longer-term growth driver. Article
• Negative Sentiment: Investors are concerned about roughly $4 billion in planned 2027 cash costs, much of it tied to pipeline investment, while visibility into future revenue growth remains limited. Coverage also noted that the 2026 revenue outlook may fall short of analyst expectations, tempering the more optimistic growth forecast. Article

Moderna Price Performance

MRNA opened at $223.37 on Friday. The firm has a market cap of $90.38 billion, a P/E ratio of -31.46 and a beta of 1.16. The firm has a 50-day moving average of $201.67 and a 200 day moving average of $96.41. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.47 and a current ratio of 3.62. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $280.80.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $1.48. The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $890.25 million. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. Moderna’s quarterly revenue was up 29.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.51) EPS. On average, research analysts expect that Moderna, Inc. will post -5.34 EPS for the current year.

Insiders Place Their Bets

In related news, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the completion of the sale, the insider owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. This trade represents a 4.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James M. Mock sold 34,836 shares of the business’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the sale, the chief financial officer owned 59,375 shares in the company, valued at $7,985,343.75. This represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 197,251 shares of company stock valued at $33,875,904 over the last ninety days. 10.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on MRNA. Citigroup reissued a “sell” rating on shares of Moderna in a research report on Friday, October 23rd. TD Cowen reiterated a “buy” rating on shares of Moderna in a research note on Wednesday, October 21st. Bradesco Corretora raised shares of Moderna to an “outperform” rating in a research report on Friday, August 28th. CLSA upgraded Moderna to an “outperform” rating in a research note on Friday, August 28th. Finally, Brookline Capital Markets reaffirmed a “buy” rating on shares of Moderna in a report on Wednesday, August 19th. Six equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $113.75.

About Moderna

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.